Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. [PDF]
PLoS ONE, 2013 AIM: Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe (-/-)) mice. It remains to be seen, however, whether this effect stems from increased levels
Michishige Terasaki +11 more
doaj +1 more source
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]
, 2017 Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B. +7 more
core +2 more sources
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Elevated free fatty acids (FFAs) are a risk factor for type 2 diabetes. Endothelial dysfunction induced by high levels of FFAs is one of the mechanisms related to the progression of diabetes. In clinical diabetes care, DPP-4 inhibitors have been shown to
Yanyan Qi +3 more
doaj +1 more source
Journal of Diabetology, 2023 Background: Branded generics offer comparable therapeutic benefits at a lower cost, making them essential in healthcare systems worldwide. Vildagliptin, a widely prescribed antidiabetic medication, is available in various branded generic forms.
Shambo S Samajdar +5 more
doaj +1 more source
Combined saline and vildagliptin induced M2 macrophage polarization in hepatic injury induced by acute kidney injury [PDF]
PeerJ, 2023 Acute kidney injury (AKI) is a prevalent medical condition accompanied by mutual affection of other organs, including the liver resulting in complicated multiorgan malfunction.
Shaimaa N. Amin +5 more
doaj +2 more sources
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes [PDF]
, 2017 This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record.The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management ...
Paldanius, PM, Strain, WD
core +1 more source
Journal of Diabetes Investigation, 2019 A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped.
Takatoshi Anno +6 more
doaj +1 more source
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]
, 2018 Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo +10 more
core +1 more source
The Influence of Excipients’ Chemical Nature on the Degradation of Metformin and Vildagliptin [PDF]
Kemija u IndustrijiThe influence of the chemical nature of excipients (magnesium stearate, povidone, microcrystalline cellulose, lactose, crospovidone, and talc) on the degradation of metformin and vildagliptin was tested by forced degradation, using acid hydrolysis, base ...
Amra Demirović +2 more
doaj +1 more source